Sign in
Active, not recruitingPhase 3

R21/Matrix-M in African Children Against Clinical Malaria

Key facts

Who runs it
University of Oxford
Where
United Kingdom1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
Phase
Phase 3
People taking part
4,800 people, planned
Started
29 Apr 2021
Expected to end
Apr 2028
Type of study
Interventional, 11 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • R21/Matrix-M
  • Rabies vaccine, Hepatitis A vaccine or Meningococcal vaccine
Record updated
23 February 2026

Who can take part

Age
5 months to 36 months
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • All participants must satisfy the following criteria at study entry:
  • The child is 5-36 months of age at the time of first vaccination
  • Signed informed consent/thumb-printed and witnessed informed consent obtained from the parent(s)/guardian(s) of the child to join the trial
  • The investigator believes that the parents/guardians can and will comply with the requirements of the protocol if the child is enrolled in the study
  • The child is a permanent resident of the study area and likely to remain a resident for the duration of the trial

Who cannot take part

  • The child has previously received a malaria vaccine
  • The child has a history of allergic reactions, significant IgE-mediated events or anaphylaxis to previous immunisations
  • The child has been administered immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate
  • Children currently meeting the WHO criteria for HIV disease of stage 3 or 4 severity. A previous history of stage 3 or 4 disease is not an exclusion. Note: There will be no routine testing for HIV. Positive diagnoses will be recorded at screening if known
  • The child has received an investigational drug or vaccine other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period
  • The child has a history of allergic disease or reactions likely to be exacerbated by any component of the malaria or control vaccine
  • The child has any significant disease, disorder or situation which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial; Additional exclusion criteria for second phase of the trial (addition of second and third booster doses)
  • Hypersensitivity to neomycin (Hepatitis A vaccine may contain traces of this)
  • The child has anaemia associated with clinical signs of symptoms of decompensation, or a haemoglobin of ≤ 5.0 g/dL
  • The child has an acute or chronic, clinically significant pulmonary, cardiovascular, gastrointestinal, endocrine, neurological, skin, hepatic or renal functional abnormality, as determined by medical history, physical examination or laboratory tests
  • The following criteria should be checked at the time of study entry. If any apply, the participant must not be included:
  • The child is enrolled in another malaria intervention trial
  • The child has major congenital defects
  • The child has had a blood transfusion within one month of enrolment
  • The child has malnutrition requiring hospital admission
  • The child is currently participating in another clinical trial if likely to affect data interpretation of this trial

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

A Phase III randomized controlled multi-centre trial to evaluate the efficacy of the R21/Matrix-M vaccine in African children against clinical malaria

The 11 groups in the trial

  • Standard Regime - Group 1-1Treatment being tested

    R21/Matrix-M at primary series and first booster, control vaccine at second and third booster, n = 400, 5-36 months olds

    Treatment: R21/Matrix-M and Rabies vaccine, Hepatitis A vaccine or Meningococcal vaccine

  • Standard Regime - Group 1-2Treatment being tested

    R21/Matrix-M at primary series, first booster and second booster, control vaccine at third booster, n = 400, 5-36 months olds

    Treatment: R21/Matrix-M and Rabies vaccine, Hepatitis A vaccine or Meningococcal vaccine

  • Standard Regime - Group 1-3Treatment being tested

    R21/Matrix-M at primary series and first booster, control vaccine at second booster and R21/Matrix-M at third booster, n = 400, 5-36 months olds

    Treatment: R21/Matrix-M and Rabies vaccine, Hepatitis A vaccine or Meningococcal vaccine

  • Standard Regime - Group 1-4Treatment being tested

    R21/Matrix-M at primary series, first booster, second booster and third booster, n = 400, 5-36 months olds

    Treatment: R21/Matrix-M

  • Standard Regime - Group 2Placebo, for comparison

    Control vaccine at primary series, first booster, second booster and third booster, n=800, 5-36 month olds

    Treatment: Rabies vaccine, Hepatitis A vaccine or Meningococcal vaccine

  • Seasonal Regime - Group 5Treatment being tested

    Group 3-1 for the initial part of the trial and first extension - R21/Matrix-M at primary series and first booster, control vaccine at second and third booster, n = 400, 5-36 months olds. For the school age booster extension, group 3-1 has been randomised into two groups: group 5 and 6. Group 5 will receive another dose of R21/Matrix-M.

    Treatment: R21/Matrix-M and Rabies vaccine, Hepatitis A vaccine or Meningococcal vaccine

  • Seasonal Regime - Group 3-2Treatment being tested

    R21/Matrix-M at primary series, first booster and second booster, control vaccine at third booster, n = 400, 5-36 months olds. For the school age booster extension, this group will receive no further vaccination and will be followed up for a further two years.

    Treatment: R21/Matrix-M and Rabies vaccine, Hepatitis A vaccine or Meningococcal vaccine

  • Seasonal Regime - Group 3-3Treatment being tested

    R21/Matrix-M at primary series and first booster, control vaccine at second booster and R21/Matrix-M at third booster, n = 400, 5-36 months olds. For the school age booster extension, this group will receive no further vaccination and will be followed up for a further two years.

    Treatment: R21/Matrix-M and Rabies vaccine, Hepatitis A vaccine or Meningococcal vaccine

  • Seasonal Regime - Group 3-4Treatment being tested

    R21/Matrix-M at primary series, first booster, second booster and third booster, n = 400, 5-36 months olds. For the school age booster extension, this group will receive no further vaccination and will be followed up for a further two years.

    Treatment: R21/Matrix-M

  • Seasonal Regime - Group 4Placebo, for comparison

    Control vaccine at primary series, first booster, second booster and third booster, n=800, 5-36 month olds. For the school age booster extension, this group will receive one further booster of the control vaccine.

    Treatment: Rabies vaccine, Hepatitis A vaccine or Meningococcal vaccine

  • Seasonal Regime - Group 6Treatment being tested

    Group 3-1 for the initial part of the trial and first extension - R21/Matrix-M at primary series and first booster, control vaccine at second and third booster, n = 400, 5-36 months olds. For the school age booster extension, group 3-1 has been randomised into two groups: group 5 and 6. Group 6 will receive a control vaccine.

    Treatment: R21/Matrix-M and Rabies vaccine, Hepatitis A vaccine or Meningococcal vaccine

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase III Randomized Controlled Multi-centre Trial to Evaluate the Efficacy of the R21/Matrix-M Vaccine in African Children Against Clinical Malaria
Publications
Record updated
23 February 2026